{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:58:47Z","timestamp":1794866327611,"version":"4.9.1"},"reference-count":16,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["AMED23ck0106745h0002"],"award-info":[{"award-number":["AMED23ck0106745h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,8,1]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>In an MRI-guided linear accelerator (MR-LINAC) system, the planned doses for organs at risk and for tumours are assessed by MR imaging and re-contouring at every treatment. This allows treatment to be safer and more precise by ensuring that it is suitable for the state of the patient\u2019s organs on that day, as well as by allowing images to be acquired during radiation therapy to prevent radiation while organs are in motion.<\/jats:p>\n                  <jats:p>Here, we will conduct a confirmatory study of two-fractionated stereotactic magnetic resonance-guided adaptive radiation therapy for patients with localised prostate cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>This will be a single-arm study to demonstrate the safety and efficacy of ultra-hypofractionated radiation (26\u2009Gy\/2 Fr) using an MR-LINAC system in patients with very low-intermediate risk prostate cancer.<\/jats:p>\n                  <jats:p>The primary endpoint will be the incidence of grade \u22652 acute urinary tract adverse events occurring within 90 days of the start of radiation therapy.<\/jats:p>\n                  <jats:p>The sample size has been determined to be 58.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This study is performed in accordance with Ethical Guidelines for Medical and Health Research Involving Human Subjects, published by Japan\u2019s Ministry of Education, Science and Technology and the Ministry of Health, Labour and Welfare and the modified act on the Protection of Personal Information as well as the Declaration of Helsinki. This study was approved by the institutional ethics committee of the National Cancer Center on 20 November 2021.<\/jats:p>\n                  <jats:p>The findings of this trial will be submitted to an international peer-reviewed journal and the key findings will be presented at an international scientific conference.<\/jats:p>\n                  <jats:p>Authorship will be ascribed in accordance with the International Committee of Medical Journal Editors guidance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>UMIN000049746.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-082899","type":"journal-article","created":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T10:55:43Z","timestamp":1724583343000},"page":"e082899","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Two-fractionated stereotactic magnetic resonance-guided adaptive radiation therapy for patients with prostate cancer (SMART PRO trial): protocol for a confirmatory clinical trial"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0421-5805","authenticated-orcid":false,"given":"Sadamoto","family":"Zenda","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa, Japan"},{"name":"Department of Supportive and Palliative Care Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tairo","family":"Kashihara","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Integrative Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto-Shi, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kadoya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ei","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Saitama Medical University, Iruma-gun, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2446-7716","authenticated-orcid":false,"given":"Takashi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Jingu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Osaka Metropolitan University Graduate School of Medicine School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Uno","sequence":"additional","affiliation":[{"name":"Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Igaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,25]]},"reference":[{"key":"2025101814364215000_14.8.e082899.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.08.030"},{"key":"2025101814364215000_14.8.e082899.2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients","volume":"110","author":"van Dams","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025101814364215000_14.8.e082899.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30569-8"},{"key":"2025101814364215000_14.8.e082899.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02857-2"},{"key":"2025101814364215000_14.8.e082899.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30102-4"},{"key":"2025101814364215000_14.8.e082899.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31131-6"},{"key":"2025101814364215000_14.8.e082899.7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijrobp.2011.05.058","article-title":"Improving positioning in high-dose radiotherapy for prostate cancer: safety and visibility of frequently used gold fiducial markers","volume":"83","author":"Fonteyne","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025101814364215000_14.8.e082899.8","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-018-1029-7","article-title":"Evaluation of gold fiducial marker manual localisation for magnetic resonance-only prostate radiotherapy","volume":"13","author":"Maspero","year":"2018","journal-title":"Radiat Oncol"},{"key":"2025101814364215000_14.8.e082899.9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tipsro.2022.08.004","article-title":"Online adaptive MR-guided radiotherapy: Conformity of contour adaptation for prostate cancer, rectal cancer and lymph node oligometastases among radiation therapists and radiation oncologists","volume":"23","author":"Rasing","year":"2022","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"2025101814364215000_14.8.e082899.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.08.021"},{"key":"2025101814364215000_14.8.e082899.11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2019.03.002","article-title":"Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial","volume":"135","author":"Alayed","year":"2019","journal-title":"Radiother Oncol"},{"key":"2025101814364215000_14.8.e082899.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.01.023"},{"key":"2025101814364215000_14.8.e082899.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11324.x"},{"key":"2025101814364215000_14.8.e082899.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b3985","article-title":"The tyranny of power: is there a better way to calculate sample size?","volume":"339","author":"Bland","year":"2009","journal-title":"BMJ"},{"key":"2025101814364215000_14.8.e082899.15","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/cncr.34836","article-title":"Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: Asystematic review and meta-analysis","volume":"129","author":"Leeman","year":"2023","journal-title":"Cancer"},{"key":"2025101814364215000_14.8.e082899.16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.ijrobp.2023.12.035","article-title":"Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial","volume":"118","author":"Neylon","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-082899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:36:48Z","timestamp":1760823408000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-082899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":16,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,25]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/bmjopen-2023-082899"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-082899","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}